Cosentyx (secukinumab) is a human interleukin-17A (IL-17A) antagonist indicated for the treatment of several conditions, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. The dosage of Cosentyx does not typically require adjustment based on body weight or obesity status [1][2].

The prescribing information for Cosentyx provides recommended dosages for the different indications, without specific adjustments for obese patients [1]. For plaque psoriasis, the recommended dosage is 300 mg (as two 150 mg injections) at Weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks [1]. For psoriatic arthritis and ankylosing spondylitis, the recommended dosage is 150 mg at Weeks 0, 1, 2, 3, and 4, followed by 150 mg every 4 weeks [1].

However, individual patient needs may necessitate dosage adjustments. In such cases, healthcare providers should consider factors such as the patient's response to treatment, disease severity, and the presence of concomitant conditions or medications [1].

In summary, Cosentyx dosage does not have a specific adjustment for obese patients, but healthcare providers may need to individualize the dosage based on patient-specific factors.

Sources:
[1] Cosentyx (secukinumab) [Prescribing Information]. Novartis Pharmaceuticals Corporation; 2021. Available from: <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>
[2] DrugPatentWatch. Cosentyx (secukinumab) [Patent Information]. Available from: <https://www.drugpatentwatch.com/patent/cosentyx-secukinumab/>